6.3 Antithrombotic Agents, Antiarrhythmics & Lipid Management

6.3 Antithrombotic Agents, Antiarrhythmics & Lipid Management

[!NOTE] ANCC Clinical Scope: Cardiovascular nurses must demonstrate deep clinical expertise across three pivotal pharmacologic areas: antithrombotic therapy (antiplatelets and anticoagulants), antiarrhythmic agents (Vaughan Williams classification, toxicity monitoring, and emergency ACLS drugs), and intensive lipid-lowering pharmacotherapy. These competencies are tested extensively throughout Domain II and Domain III.

---

Antiplatelet Pharmacotherapy & Interventional Cardiology

Platelets play the primary role in arterial thrombosis following atherosclerotic plaque rupture or percutaneous coronary intervention (PCI).

1. Aspirin (Acetylsalicylic Acid)

• Mechanism: Irreversibly acetylates and inactivates platelet cyclooxygenase-1 (COX-1), permanently preventing the conversion of arachidonic acid to Thromboxane $A_2$ ($TXA_2$), a potent platelet agonist and vasoconstrictor. Because platelets lack nuclei and cannot synthesize new proteins, inhibition persists for the platelet lifespan (7 to 10 days).
• Dosing: Acute ACS loading dose is 162 to 325 mg non-enteric-coated tablet, chewed for rapid buccal and gastric absorption. Long-term maintenance dose is 81 mg daily (baby aspirin) indefinitely.
• Adverse Effects: Upper GI mucosal ulceration, dyspepsia, bleeding, and aspirin-exacerbated respiratory disease (Samter's triad: asthma, nasal polyps, aspirin sensitivity).

2. Oral $P2Y_{12}$ Receptor Inhibitors

Oral $P2Y_{12}$ antagonists prevent adenosine diphosphate (ADP) from binding to its purinergic receptor on platelets, blocking inside-out signaling that activates the Glycoprotein IIb/IIIa complex.

3. Dual Antiplatelet Therapy (DAPT) Duration & Stent Thrombosis

• Standard DAPT Duration: Following PCI for Acute Coronary Syndrome (STEMI or NSTEMI), guidelines mandate a minimum of 12 months of DAPT (aspirin 81 mg daily plus a potent $P2Y_{12}$ inhibitor, preferably ticagrelor or prasugrel). For elective PCI in stable ischemic heart disease with drug-eluting stents (DES), a minimum of 6 months is recommended.
• High Bleeding Risk (HBR): Regimens may be shortened to 1 to 3 months followed by single antiplatelet monotherapy.
• Critical Nursing Alert: Premature discontinuation of DAPT is the single greatest risk factor for catastrophic stent thrombosis, which frequently presents as massive transmural STEMI or sudden cardiac death.

4. Intravenous Glycoprotein IIb/IIIa Inhibitors

• Agents: Eptifibatide (Integrilin) and Tirofiban (Aggrastat).
• Mechanism: Reversibly block the final common pathway of platelet aggregation by preventing soluble fibrinogen and von Willebrand factor from bridging adjacent GP IIb/IIIa receptor complexes.
• Clinical Application: Administered intravenously as a weight-based bolus followed by continuous infusion in high-risk patients undergoing PCI with high thrombus burden or procedural 'no-reflow'.
• Safety Monitoring: Check baseline platelet count and repeat within 2 to 4 hours of initiation to detect acute profound drug-induced thrombocytopenia. Require dose reduction in renal disease.

---

Anticoagulation: Heparins, Warfarin & DOACs

Coagulation Pathway Targets:

[ UFH + AT-III ]        ───> Inhibits Thrombin (IIa) and Factor Xa (1:1 Ratio)
[ LMWH (Enoxaparin) ]   ───> Preferentially Inhibits Factor Xa over IIa (4:1 Ratio)
[ Warfarin ]            ───> Depletes Vitamin K Factors: II, VII, IX, X + Proteins C & S
[ DOACs: Xa Inhibitors] ───> Apixaban, Rivaroxaban (Reversal: Andexanet Alfa)
[ DOACs: IIa Inhibitor] ───> Dabigatran (Reversal: Idarucizumab)

1. Unfractionated Heparin (UFH)

• Mechanism: Binds to Antithrombin III (AT-III), producing a conformational change that accelerates AT-III inhibition of Factor IIa (thrombin) and Factor Xa by 1,000-fold.
• Monitoring: Titrated using weight-based protocols to a target activated partial thromboplastin time (aPTT) of 1.5 to 2.5 times control (typically 60 to 80 seconds) or anti-Factor Xa levels of 0.3 to 0.7 IU/mL.
• Reversal: Protamine Sulfate (1 mg neutralizes ~100 units of UFH administered in the preceding 2–3 hours; administer via slow IV push over 10 minutes to avoid anaphylaxis and hypotension).

2. Heparin-Induced Thrombocytopenia (Type II HIT)

• Pathophysiology: Severe immune-mediated reaction caused by IgG antibodies directed against Platelet Factor 4 (PF4)-heparin complexes. The IgG-PF4-heparin complexes bind to platelet Fc$\gamma$RIIa receptors, triggering massive platelet activation, consumption, and systemic thrombin generation.
• Clinical Recognition (The 4Ts Rule):
  • Platelet count drops by $\ge 50%$ from baseline or absolute count falls below $100,000/\mu L$.
  • Onset typically occurs 5 to 10 days after heparin initiation (or within hours if exposed to heparin within the previous 100 days).
  • Paradoxical Thrombosis: Despite severe thrombocytopenia, HIT is a highly prothrombotic state. Patients develop deep vein thrombosis, pulmonary embolism, ischemic stroke, acute MI, or arterial limb ischemia.
• Mandatory Nursing Protocol for Suspected HIT:
  1. STOP all heparin products immediately (including continuous infusions, subcutaneous prophylactic injections, heparin flushes, and heparin-coated central lines).
  2. Never administer platelet transfusions: Transfused platelets bind PF4-heparin antibodies, worsening the thrombotic storm ('fuel on the fire').
  3. Do NOT initiate warfarin acutely: Warfarin rapidly depletes protein C (short half-life of 6–8 hours) before lowering procoagulant factors, precipitating microvascular thrombosis, warfarin-induced skin necrosis, and venous limb gangrene. Warfarin is delayed until platelets recover to $\ge 150,000/\mu L$.
  4. Initiate an alternative non-heparin parenteral anticoagulant: Start a direct thrombin inhibitor (DTI)—Argatroban (hepatically cleared, monitored via aPTT) or Bivalirudin (cleared renally/enzymatically).

3. Low Molecular Weight Heparin (LMWH: Enoxaparin / Lovenox)

• Mechanism: Smaller heparin fragments that preferentially inhibit Factor Xa over Factor IIa (ratio 3:1 to 4:1).
• Clinical Utility: Subcutaneous administration with highly predictable bioavailability; routine laboratory monitoring is unnecessary in stable patients. Anti-Factor Xa levels (peak drawn 4 hours post-dose) are monitored in pregnancy, morbid obesity, or renal dysfunction.
• Renal Dosing: Primarily excreted renally. When $CrCl < 30\text{ mL/min}$, the therapeutic dose must be reduced from 1 mg/kg every 12 hours to 1 mg/kg every 24 hours.

4. Warfarin (Coumadin)

• Mechanism: Oral vitamin K antagonist that competitively inhibits vitamin K epoxide reductase (VKORC1), depleting functional hepatic synthesis of clotting factors II, VII, IX, and X, as well as anticoagulant Proteins C and S.
• Laboratory Monitoring & INR Targets:
  • Monitored via Prothrombin Time / International Normalized Ratio (PT/INR).
  • Target INR 2.0 to 3.0: Non-valvular atrial fibrillation, deep vein thrombosis, pulmonary embolism, bioprosthetic heart valves.
  • Target INR 2.5 to 3.5: Mechanical mitral valves, mechanical aortic valves with high-risk thromboembolic factors.
• Reversal Protocols:
  • Vitamin K1 (Phytonadione): Oral (preferred for non-bleeding elevated INR) or slow IV infusion. Avoid subcutaneous or intramuscular routes due to erratic absorption and hematoma risk.
  • 4-Factor Prothrombin Complex Concentrate (4F-PCC / Kcentra): Contains factors II, VII, IX, X, Protein C, and Protein S. Preferred over Fresh Frozen Plasma (FFP) for urgent reversal of life-threatening bleeding due to rapid INR normalization without volume overload.

5. Direct Oral Anticoagulants (DOACs)

• Direct Factor Xa Inhibitors: Apixaban (Eliquis), Rivaroxaban (Xarelto), and Edoxaban (Savaysa).
• Direct Thrombin Inhibitor: Dabigatran (Pradaxa).
• Advantages: Fixed oral dosing, rapid onset (1 to 3 hours), predictable half-lives (~12 hours), significantly lower rates of fatal intracranial hemorrhage, and no routine INR monitoring.
• Specific Reversal Agents:
  • Idarucizumab (Praxbind): Humanized monoclonal antibody fragment that binds free and thrombin-bound dabigatran with 350-fold higher affinity than thrombin. Dosed as 5 g IV (two 2.5 g vials).
  • Andexanet alfa (Andexxa): Recombinant modified human Factor Xa decoy protein that binds and sequesters apixaban and rivaroxaban during life-threatening bleeding.

---

Antiarrhythmic Drugs: Vaughan Williams Classification

Antiarrhythmic drugs are categorized by their primary electrophysiologic mechanism according to the Vaughan Williams classification system.

Amiodarone Toxicity Surveillance

Amiodarone possesses Class I, II, III, and IV electrophysiologic properties. It has an immense volume of distribution, high lipophilicity, and an elimination half-life of 40 to 60 days. Because amiodarone contains 37% iodine by molecular weight, it exhibits severe multi-organ toxicities requiring rigorous monitoring:

1. Pulmonary Toxicity: Subacute cough, progressive dyspnea, pleuritic pain, and diffuse interstitial infiltrates (pulmonary fibrosis / interstitial pneumonitis). Obtain baseline chest X-ray and Pulmonary Function Tests with DLCO, repeating annually or with new pulmonary symptoms.
2. Thyroid Dysfunction: Amiodarone inhibits peripheral conversion of T4 to T3 and releases large amounts of free iodine. Causes Amiodarone-Induced Hypothyroidism (AIH) in up to 20% of patients and Amiodarone-Induced Thyrotoxicosis (AIT) in 3% to 5%. Check baseline and serial TSH/free T4 every 6 months.
3. Hepatic Toxicity: Elevates serum transaminases (AST/ALT) and can induce chronic cirrhosis. Check baseline and serial LFTs every 6 months.
4. Ocular Toxicity: Causes corneal microdeposits in nearly 100% of patients taking the drug for $>6\text{ months}$ (usually asymptomatic). Optic neuropathy and optic neuritis leading to permanent blindness can occur; patients must report visual changes immediately.
5. Dermatologic: Slate-gray or blue-gray skin discoloration in sun-exposed areas; severe photosensitivity.
6. Drug Interactions: Potently inhibits CYP2C9, CYP3A4, and P-glycoprotein. Doubles circulating levels of warfarin (reduce warfarin dose by 30% to 50%) and digoxin (reduce digoxin dose by 50% upon initiating amiodarone).

Dofetilide (Tikosyn) Inpatient Initiation Protocol

• Mechanism: Pure $I_{Kr}$ potassium channel blocker used for conversion and maintenance of normal sinus rhythm in atrial fibrillation.
• Mandatory Inpatient Telemetry: Must be initiated in an inpatient hospital setting with continuous ECG telemetry monitoring for a minimum of 72 hours (3 full days).
• Dosing & QTc Monitoring: Dosed according to baseline creatinine clearance and QTc. Measure ECG 2 to 3 hours after each dose.
• Safety Threshold: If the baseline QTc exceeds 440 ms (or 500 ms with ventricular conduction delay), dofetilide is contraindicated. If the QTc increases by $>15%$ above baseline or exceeds 500 ms at any point after initiation, down-titrate or immediately discontinue the drug to prevent lethal Torsades de Pointes.

Emergency Miscellaneous Antiarrhythmics

• Adenosine:
  • Mechanism: Stimulates myocardial $A_1$ receptors, opening inward rectifier potassium channels and transiently producing complete atrioventricular nodal conduction block.
  • Clinical Role: Drug of choice for terminating stable narrow-complex Paroxysmal Supraventricular Tachycardia (PSVT / AVNRT / AVRT).
  • Administration Protocol: Administer 6 mg rapid IV push over 1 to 2 seconds through a large-bore proximal IV line (antecubital or central line), followed IMMEDIATELY by a 20 mL normal saline flush, elevating the arm. If conversion does not occur within 1 to 2 minutes, administer a second rapid dose of 12 mg IV push. Warn the patient that they will feel severe chest tightness, flushing, and dyspnea, with several seconds of asystole on the monitor.
• Atropine:
  • Mechanism: Anticholinergic / antimuscarinic agent that blocks vagal parasympathetic input to the SA and AV nodes.
  • Clinical Role: First-line pharmacotherapy for symptomatic acute sinus bradycardia (ACLS: 1 mg IV push every 3 to 5 minutes, up to a maximum cumulative dose of 3 mg). Ineffective in infranodal blocks (Mobitz II and third-degree AV block with wide QRS escape rhythms), which require immediate pacing.

---

Evidence-Based Lipid Management

Lipid management aims to reduce circulating apolipoprotein B-containing atherogenic particles to stabilize plaques and prevent recurrent cardiovascular events.

Statin Adverse Effects & Nursing Monitoring

• Statin-Associated Muscle Symptoms (SAMS): Symmetrical proximal muscle aching, stiffness, or weakness without CK elevation. If severe pain occurs, check serum Creatine Kinase (CK).
• Rhabdomyolysis: Rare, life-threatening complication characterized by marked CK elevations ($> 10\times\text{ upper limit of normal}$), myoglobinuria, dark tea-colored urine, and acute renal failure. Discontinue statin immediately and hydrate aggressively.
• Hepatic Monitoring: Obtain baseline ALT/AST. Routine serial LFT monitoring is no longer recommended unless the patient develops jaundice, malaise, or right upper quadrant abdominal pain.

Non-Statin Lipid-Lowering Therapies

1. Ezetimibe (Zetia): Selectively inhibits the Niemann-Pick C1-Like 1 (NPC1L1) sterol transporter in the brush border of the small intestine, decreasing dietary and biliary cholesterol absorption. Added to maximally tolerated statin therapy to provide an additional 15% to 20% LDL-C reduction (IMPROVE-IT trial).
2. PCSK9 Inhibitors (Evolocumab / Repatha, Alirocumab / Praluent): Human monoclonal antibodies that bind Proprotein Convertase Subtilisin/Kexin Type 9. PCSK9 normally targets hepatic LDL receptors for lysosomal degradation. By inactivating PCSK9, these agents preserve LDL receptors, increasing clearance of circulating LDL-C and achieving profound 50% to 60% LDL-C reductions beyond statins. Administered via subcutaneous injection every 2 to 4 weeks.
3. Bempedoic Acid (Nexletol): Inhibits ATP Citrate Lyase (ACL), an enzyme acting upstream of HMG-CoA reductase in the hepatic cholesterol biosynthesis pathway. Because the activating enzyme is present in the liver but absent in skeletal muscle, bempedoic acid does not cause muscle aches or myopathy, making it an outstanding agent for statin-intolerant patients (CLEAR Outcomes trial).